Utilizing Artificial Intelligence to Optimize Sustainable Modern Precision Drug Development

Junius Gian Ginting

doi:10.55927/fjmr.v5i7.129

Authors

Junius Gian Ginting Universitas Senior Medan

DOI:

https://doi.org/10.55927/fjmr.v5i7.129

Keywords:

Artificial Intelligence, Precision Drug Development, Sustainable Pharmaceutical Innovation

Abstract

Artificial Intelligence (AI) has emerged as a transformative technology in the pharmaceutical industry, offering innovative solutions to accelerate drug discovery, enhance precision medicine, and improve sustainability in healthcare systems. Conventional drug development is often characterized by lengthy timelines, high costs, and significant failure rates, creating a need for more efficient and data-driven approaches. This study aims to analyze the role of AI in optimizing sustainable modern precision drug development. The research employed a Systematic Literature Review (SLR) method following the PRISMA 2020 framework. Literature was collected from major scientific databases, including Scopus, Web of Science, PubMed, ScienceDirect, SpringerLink, IEEE Xplore, and Google Scholar. From an initial pool of 152 articles, 10 studies published between 2020 and 2025 met the inclusion criteria and were analyzed using thematic synthesis. The findings reveal that AI significantly accelerates drug discovery, supports personalized medicine through multi-omics data integration, enhances sustainability by improving resource efficiency, and drives pharmaceutical innovation through generative AI technologies. However, challenges related to data quality, transparency, ethics, and regulatory compliance remain critical barriers. Overall, AI represents a strategic enabler for sustainable, efficient, and patient-centered pharmaceutical development.

References

Alizadehsani, R., Oyelere, S. S., Hussain, S., Calixto, R. R., de Albuquerque, V. H. C., Roshanzamir, M., Rahouti, M., & Jagatheesaperumal, S. K. (2023). Explainable Artificial Intelligence for Drug Discovery and Development: A Comprehensive Survey. arXiv. https://doi.org/10.48550/arXiv.2309.12177

Alowais, S. A., Alghamdi, S. S., Alsuhebany, N., Alqahtani, T., Alshaya, A. I., Almohareb, S. N., Aldairem, A., Alrashed, M., Bin Saleh, K., Badreldin, H. A., Al Yami, M. S., Al Harbi, A., Albekairy, A. M., & Alzahrani, T. (2023). Revolutionizing healthcare: The role of artificial intelligence in clinical practice. BMC Medical Education, 23(1), 689. https://doi.org/10.1186/s12909-023-04698-z

Chen, J., Wang, Y., & Li, H. (2024). Artificial intelligence and precision medicine: Emerging trends and future directions. Journal of Personalized Medicine, 14(3), 245–260.

Fornasier, G., Francescon, S., Baldo, P., & Hossain, M. A. (2024). Drug discovery in the context of precision medicine and artificial intelligence. Exploration of Drug Science, 2(3), 42–53.

Ghislat, G., Hernandez-Hernandez, S., Piyawajanusorn, C., & Ballester, P. J. (2024). Data-centric challenges with the application and adoption of artificial intelligence for drug discovery. Expert Opinion on Drug Discovery, 19(9), 1023–1034.

Khan, M. K., Raza, M., Shahbaz, M., Hussain, I., Khan, M. F., Xie, Z., Shah, S. S. A., Tareen, A. K., Bashir, Z., & Khan, K. (2024). The recent advances in the approach of artificial intelligence towards drug discovery. Frontiers in Chemistry, 12, 1408740. https://doi.org/10.3389/fchem.2024.1408740

Kitchenham, B., & Charters, S. (2007). Guidelines for Performing Systematic Literature Reviews in Software Engineering. EBSE Technical Report.

Liu, Y., Zhang, K., Yang, X., & Wang, Y. (2024). Generative artificial intelligence in drug discovery: Basic framework, recent advances, challenges, and opportunities. Frontiers in Pharmacology, 15, 1331062. https://doi.org/10.3389/fphar.2024.1331062

Okoli, C. (2015). A guide to conducting a standalone systematic literature review. Communications of the Association for Information Systems, 37(1), 879–910.

Page, M. J., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71.

Pushkaran, A. C., & Arabi, A. A. (2024). From understanding diseases to drug design: Can artificial intelligence bridge the gap? Artificial Intelligence Review, 57(86), 1–35.

Reuters. (2026). Takeda deepens AI drug discovery push with $1.7 billion Iambic deal. Reuters.

Snyder, H. (2019). Literature review as a research methodology: An overview and guidelines. Journal of Business Research, 104, 333–339.

The Guardian. (2024). AI used to predict potential new antibiotics in groundbreaking study. The Guardian.

Thomas, J., & Harden, A. (2008). Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Medical Research Methodology, 8(1), 45.

Wang, H., Li, Y., Zhao, Q., & Sun, T. (2024). Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance. European Journal of Pharmaceutical Sciences, 203, 106938. https://doi.org/10.1016/j.ejps.2024.106938

Zhang, K., Yang, X., Wang, Y., Yu, Y., Huang, N., Li, G., Li, X., Wu, J. C., & Yang, S. (2025). Artificial intelligence in drug development. Nature Medicine, 31(1), 45–59.

Zhang, Y., Mastouri, M., & Zhang, Y. (2024). Accelerating drug discovery, development, and clinical trials by artificial intelligence. Med, 5(9), 1050–1070. https://doi.org/10.1016/j.medj.2024.07.005